CC chemokine receptor 9 (CCR9) belongs to the beta chemokine receptor family and is mainly distributed on the surface of immature T lymphocytes and enterocytes. This receptor is highly expressed in rheumatoid arthritis, colitis, type 2 diabetes, and various tumors. Therefore, more sensitive monoclonal antibodies (mAbs) need to be developed to predict the prognosis of many high CCR9 expression diseases. Because CCR9 is a structurally unstable G protein-coupled receptor, it has been difficult to develop anti-CCR9 mAbs using the traditional method. This study developed anti-human CCR9 (hCCR9) mAbs for flow cytometry using a Cell-Based Immunization and Screening (CBIS) method. Two mice were immunized with hCCR9-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/hCCR9), and hybridomas showing strong signals from CHO/hCCR9 and no signals from CHO-K1 cells were selected by flow cytometry. We established an anti-hCCR9 mAb, C9Mab-1 (IgG1, kappa), which detected hCCR9 in MOLT-4 leukemia T lymphoblast cells and CHO/hCCR9 cells by flow cytometry. Our study showed that an anti-hCCR9 mAb was developed more rapidly by the CBIS method than the previous method.
Get full access to this article
View all access options for this article.
References
1.
StrydomN, and RankinSM: Regulation of circulating neutrophil numbers under homeostasis and in disease. J Innate Immun, 2013; 5:304–314.
2.
ZlotnikA, and YoshieO: Chemokines: A new classification system and their role in immunity. Immunity, 2000; 12:121–127.
3.
RoyI, EvansDB, and DwinellMB: Chemokines and chemokine receptors: Update on utility and challenges for the clinician. Surgery, 2014; 155:961–973.
4.
GriffithJW, SokolCL, and LusterAD: Chemokines and chemokine receptors: Positioning cells for host defense and immunity. Annu Rev Immunol, 2014; 32:659–702.
5.
MillerMC, and MayoKH: Chemokines from a structural perspective. Int J Mol Sci, 2017; 18:2088.
6.
TuZ, XiaoR, XiongJ, TemboKM, DengX, XiongM, LiuP, WangM, and ZhangQ: CCR9 in cancer: Oncogenic role and therapeutic targeting. J Hematol Oncol, 2016; 9:10.
7.
ZaballosA, GutiérrezJ, VaronaR, ArdavínC, and MárquezG: Cutting edge: Identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol, 1999; 162:5671–5675.
8.
QiupingZ, JeiX, YouxinJ, WeiJ, ChunL, JinW, QunW, YanL, ChunsongH, MingzhenY, QingpingG, KejianZ, ZhiminS, QunL, JunyanL, and JinquanT: CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res, 2004; 64:7579–7587.
9.
MirandolaL, Chiriva-InternatiM, MontagnaD, LocatelliF, ZeccaM, RanzaniM, BasileA, LocatiM, CobosE, KastWM, AsseltaR, ParaboschiEM, ComiP, and ChiaramonteR: Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol, 2012; 226:713–722.
10.
Kühnelt-LeddihnL, MüllerH, EisendleK, ZelgerB, and WeinlichG: Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: A potential prognostic value for CCR7 and CCR10?. Arch Dermatol Res, 2012; 304:185–193.
11.
SinghS, SinghUP, StilesJK, GrizzleWE, and LillardJW: Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res, 2004; 10:8743–8750.
12.
ZhangZ, SunT, ChenY, GongS, SunX, ZouF, and PengR: CCL25/CCR9 Signal promotes migration and invasion in hepatocellular and breast cancer cell lines. DNA Cell Biol, 2016; 35:348–357.
13.
ZhongY, JiangL, LinH, LiB, LanJ, LiangS, ShenB, LeiZ, and ZhengW: Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma. Diagn Pathol, 2015; 10:101.
14.
JohnsonEL, SinghR, SinghS, Johnson-HolidayCM, GrizzleWE, PartridgeEE, and LillardJW: CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol, 2010; 8:62.
15.
WeingrillRB, HoshidaMS, MartinhagoCD, Correa-SilvaS, CardosoE, PalmeiraP, MarinhoCRF, and BevilacquaE: Chemokine (C-C motif) ligand 25 expressed by trophoblast cells and leukocytes bearing its receptor Ccr9: An alliance during embryo implantation?. Am J Reprod Immunol, 2018; 79:e12783.
16.
XuZ, MeiF, LiuH, SunC, and ZhengZ: C-C motif chemokine receptor 9 exacerbates pressure overload-induced cardiac hypertrophy and dysfunction. J Am Heart Assoc, 2016; 5:e003342.
17.
AmiyaT, NakamotoN, IrieJ, TanikiN, ChuPS, KodaY, MiyamotoK, YamaguchiA, ShibaS, MorikawaR, ItohH, and KanaiT: C-C motif chemokine receptor 9 regulates obesity-induced insulin resistance via inflammation of the small intestine in mice. Diabetologia, 2021; 64:603–617.
18.
WangY, YuJ, LuoX, WangX, LiM, WangL, and LiD: Abnormal regulation of chemokine TECK and its receptor CCR9 in the endometriotic milieu is involved in pathogenesis of endometriosis by way of enhancing invasiveness of endometrial stromal cells. Cell Mol Immunol, 2010; 7:51–60.
19.
LiB, WangZ, ZhongY, LanJ, LiX, and LinH: CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway. Med Oncol, 2015; 32:66.
20.
ShenX, MaileyB, EllenhornJD, ChuPG, LowyAM, and KimJ: CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg, 2009; 13:1955–1962; discussion 1962.
21.
YounBS, KimYJ, MantelC, YuKY, and BroxmeyerHE: Blocking of c-FLIP(L)—independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. Blood, 2001; 98:925–933.
22.
ZhangZ, QinC, WuY, SuZ, XianG, and HuB: CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma. Oncol Rep, 2014; 31:1629–1636.
23.
ZhouB, LengJ, HuM, ZhangL, WangZ, LiuD, TongX, YuB, HuY, DengC, LiuY, and ZhangQ: Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9. Leuk Res, 2010; 34:769–776.
24.
HeinrichEL, ArringtonAK, KoME, LuuC, LeeW, LuJ, and KimJ: Paracrine activation of chemokine receptor CCR9 enhances the invasiveness of pancreatic cancer cells. Cancer Microenviron, 2013; 6:241–245.
25.
JohnsonEL, SinghR, Johnson-HolidayCM, GrizzleWE, PartridgeEE, LillardJW, and SinghS: CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res, 2010; 3:15.
26.
SharmaPK, SinghR, NovakovicKR, EatonJW, GrizzleWE, and SinghS: CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int J Cancer, 2010; 127:2020–2030.
27.
Johnson-HolidayC, SinghR, JohnsonEL, GrizzleWE, LillardJW, and SinghS: CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol, 2011; 9:46.
28.
LeeS, HeinrichEL, LiL, LuJ, ChoiAH, LevyRA, WagnerJE, YipML, VaidehiN, and KimJ: CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist. Mol Oncol, 2015; 9:1599–1611.
29.
YokoyamaW, KohsakaH, KanekoK, WaltersM, TakayasuA, FukudaS, MiyabeC, MiyabeY, LovePE, NakamotoN, KanaiT, Watanabe-ImaiK, CharvatTT, PenfoldME, JaenJ, SchallTJ, HarigaiM, MiyasakaN, and NankiT: Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice. Arthritis Res Ther, 2014; 16:445.
30.
WurbelMA, McIntireMG, DwyerP, and FiebigerE: CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One, 2011; 6:e16442.
31.
SchmutzC, CartwrightA, WilliamsH, HaworthO, WilliamsJH, FilerA, SalmonM, BuckleyCD, and MiddletonJ: Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation. Arthritis Res Ther, 2010; 12:R161.
32.
AtanesP, LeeV, HuangGC, and PersaudSJ: The role of the CCL25-CCR9 axis in beta-cell function: Potential for therapeutic intervention in type 2 diabetes. Metabolism, 2020; 113:154394.
33.
ItaiS, FujiiY, NakamuraT, ChangYW, YanakaM, SaidohN, HandaS, SuzukiH, HaradaH, YamadaS, KanekoMK, and KatoY: Establishment of CMab-43, a sensitive and specific anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:231–235.
34.
FurusawaY, KanekoMK, and KatoY: Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells. Oncol Lett, 2020; 20:1961–1967.
35.
FurusawaY, KanekoMK, and KatoY: Establishment of an anti-CD20 monoclonal antibody (C20Mab-60) for immunohistochemical analyses. Monoclon Antib Immunodiagn Immunother, 2020; 39:112–116.
36.
KatoY, YamadaS, FurusawaY, ItaiS, NakamuraT, YanakaM, SanoM, HaradaH, FukuiM, and KanekoMK: PMab-213: A monoclonal antibody for immunohistochemical analysis against pig podoplanin. Monoclon Antib Immunodiagn Immunother, 2019; 38:18–24.
37.
FurusawaY, YamadaS, ItaiS, NakamuraT, TakeiJ, SanoM, HaradaH, FukuiM, KanekoMK, and KatoY: Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin. Biochem Biophys Rep, 2019; 18:100631.
38.
KatoY, FurusawaY, YamadaS, ItaiS, TakeiJ, SanoM, and KanekoMK: Establishment of a monoclonal antibody PMab-225 against alpaca podoplanin for immunohistochemical analyses. Biochem Biophys Rep, 2019; 18:100633.
39.
FurusawaY, KanekoMK, NakamuraT, ItaiS, FukuiM, HaradaH, YamadaS, and KatoY: Establishment of a monoclonal antibody PMab-231 for tiger podoplanin. Monoclon Antib Immunodiagn Immunother, 2019; 38:89–95.
40.
KatoY, FurusawaY, ItaiS, TakeiJ, NakamuraT, SanoM, HaradaH, YamadaS, and KanekoMK: Establishment of an anticetacean podoplanin monoclonal antibody PMab-237 for immunohistochemical analysis. Monoclon Antib Immunodiagn Immunother, 2019; 38:108–113.
41.
FurusawaY, YamadaS, NakamuraT, SanoM, SayamaY, ItaiS, TakeiJ, HaradaH, FukuiM, KanekoMK, and KatoY: PMab-235: A monoclonal antibody for immunohistochemical analysis against goat podoplanin. Heliyon, 2019; 5:e02063.
42.
FurusawaY, YamadaS, ItaiS, NakamuraT, YanakaM, SanoM, HaradaH, FukuiM, KanekoMK, and KatoY: PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin. Biochem Biophys Rep, 2019; 18:100616.
43.
FurusawaY, TakeiJ, SayamaY, YamadaS, KanekoMK, and KatoY: Development of an anti-bear podoplanin monoclonal antibody PMab-247 for immunohistochemical analysis. Biochem Biophys Rep, 2019; 18:100644.
44.
YamadaS, ItaiS, NakamuraT, YanakaM, ChangYW, SuzukiH, KanekoMK, and KatoY: Monoclonal antibody L1Mab-13 detected human PD-L1 in lung cancers. Monoclon Antib Immunodiagn Immunother, 2018; 37:110–115.
45.
YamadaS, KanekoMK, SayamaY, AsanoT, SanoM, YanakaM, NakamuraT, OkamotoS, HandaS, KomatsuY, NakamuraY, FurusawaY, TakeiJ, and KatoY: Development of novel mouse monoclonal antibodies against human CD19. Monoclon Antib Immunodiagn Immunother, 2020; 39:45–50.
46.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
47.
ChamorroS, VelaM, Franco-VillanuevaA, CarramolinoL, GutierrezJ, GomezL, LozanoM, SalvadorB, Garcia-GalloM, MartinezAC, and KremerL: Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs, 2014; 6:1000–1012.
48.
Somovilla-CrespoB, Martin MonzonMT, VelaM, Corraliza-GorjonI, SantamariaS, Garcia-SanzJA, and KremerL: 92R monoclonal antibody inhibits human CCR9(+) leukemia cells growth in NSG mice xenografts. Front Immunol, 2018; 9:77.
49.
TangDC, DeVitM, and JohnstonSA: Genetic immunization is a simple method for eliciting an immune response. Nature, 1992; 356:152–154.
50.
HazenM, BhaktaS, VijR, RandleS, KallopD, ChiangV, HotzelI, JaiswalBS, ErvinKE, LiB, WeimerRM, PolakisP, SchellerRH, JunutulaJR, and HongoJA: An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins. MAbs, 2014; 6:95–107.
51.
LiuS, WangS, and LuS: DNA immunization as a technology platform for monoclonal antibody induction. Emerg Microbes Infect, 2016; 5:e33.
52.
VijR, LinZ, SchneiderK, SeshasayeeD, and KoerberJT: Analysis of the effect of promoter type and skin pretreatment on antigen expression and antibody response after gene gun-based immunization. PLoS One, 2018; 13:e0197962.
53.
PalombaML, RobertsWK, DaoT, ManukianG, Guevara-PatinoJA, WolchokJD, ScheinbergDA, and HoughtonAN: CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res, 2005; 11:370–379.
54.
EdenT, MenzelS, WesolowskiJ, BergmannP, NissenM, DubberkeG, SeyfriedF, AlbrechtB, HaagF, and Koch-NolteF: A cDNA immunization strategy to generate nanobodies against membrane proteins in native conformation. Front Immunol, 2017; 8:1989.
55.
WangS, and LuS: DNA immunization. Curr Protoc Microbiol, 2013; 31:18.3.1–18.3.24.
56.
O'BrienJA, and LummisSC: Biolistic transfection of neuronal cultures using a hand-held gene gun. Nat Protoc, 2006; 1:977–981.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
